A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus
A study for patients with Lupus using study drug ustekinumab
Sponsor: Janssen Research & Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAQ7406
U.S. Govt. ID: NCT02349061
Contact: Anca Askanase: 212-305-0856 / ada20@cumc.columbia.edu
Additional Study Information: If you have active Systemic Lupus Erythematosus, also known as SLE or Lupus, you may be interested to learn about a clinical research study that is being conducted to study the safety and effectiveness of an investigational medication called ustekinumab for active Lupus. Eligible study participants will be provided with study medication and study-related medical care at no cost during the study.
This study is closed
Anca Askanase, MD, MPH
Do You Qualify?
Have you been diagnosed with Lupus? Yes No
Have you had Lupus symptoms for at least 3 months? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Anca Askanase